Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Prolight Diagnostics

0.20 SEK

+3.70 %

Less than 1K followers

PRLD

Nordic SME

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+3.70 %
+15.29 %
-18.33 %
-17.00 %
+59.80 %
+45.67 %
-12.60 %
-89.01 %
-50.20 %

Prolight Diagnostics develops point-of-care (POC) systems. These are small mobile instruments with disposable test cards that can perform In-Vitro Diagnostic (IVD) tests from a drop of blood. The POC system can contribute to faster and more accurate diagnoses of acute conditions. The company's launch product will be a highly sensitive measurement of troponin to be able to determine and exclude heart attacks.

Read more
Market cap
236.08M SEK
Turnover
402.1K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.2
2026

Annual report '25

26.5
2026

Interim report Q1'26

26.5
2026

General meeting '26

All
Press releases
3rd party
ShowingAll content types
Regulatory press release12/5/2025, 10:00 AM

THE NOMINATION COMMITTEE APPOINTED FOR THE ANNUAL GENERAL MEETING 2026

Prolight Diagnostics
Regulatory press release12/4/2025, 9:00 AM

Prolight announces timetable for share reverse split

Prolight Diagnostics
Regulatory press release11/27/2025, 7:00 AM

Prolight Diagnostics publishes quarterly report Q3, 2025

Prolight Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release11/19/2025, 1:45 PM

Extraordinary general meeting of Prolight Diagnostics AB (publ) on 19 November 2025

Prolight Diagnostics
Press release11/17/2025, 11:40 AM

BioStock publishes article about Prolight Diagnostics continued preparations to bring the Psyros platform to market

Prolight Diagnostics
Press release11/17/2025, 10:26 AM

BioStock: Final adjustments and validation take center stage at Prolight Diagnostics

Prolight Diagnostics
Press release11/5/2025, 1:55 PM

Prolight Diagnostics publishes investor letter for November 2025

Prolight Diagnostics
Regulatory press release10/17/2025, 10:00 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)

Prolight Diagnostics
Press release8/29/2025, 11:40 AM

Emergers publishes updated analysis for Prolight Diagnostics

Prolight Diagnostics
Third party research8/29/2025, 6:18 AM

Prolight: Financing and partner interest strengthen case ahead of regulatory study - Emergers

In Q2, Prolight reported initial positive data from its ongoing whole blood study at St Thomas’ Hospital in London, showing equivalence between whole blood and plasma and thereby confirming the robust clinical performance of the PsyrosTM POC platform...

Prolight Diagnostics
Press release8/29/2025, 6:00 AM

Emergers: Equity Research | PROLIGHT: Financing and partner interest strengthen case ahead of regulatory study

Prolight Diagnostics
Regulatory press release8/28/2025, 6:00 AM

Prolight Diagnostics publishes half-year report, 2025

Prolight Diagnostics
Press release8/27/2025, 6:00 AM

Prolight receives Notice of Intention to Grant in Europe for third Psyros™ patent

Prolight Diagnostics
Press release8/1/2025, 9:00 AM

Prolight Diagnostics publishes investor letter for August 2025

Prolight Diagnostics
Press release7/21/2025, 6:00 AM

Prolight secures patent in Japan for Psyros™ technology

Prolight Diagnostics
Regulatory press release7/15/2025, 12:00 PM

Last day of trading in BTAs – conversion of BTAs into shares

Prolight Diagnostics
Third party research7/3/2025, 7:19 AM

Prolight: Fully subscribed rights issue strengthens Psyros case ahead of commercial partnerships - Emergers

Prolight announced that its rights issue was fully subscribed, eliminating near-term financing risk and securing the capital needed to finalise the development, verification and pilot production of the PsyrosTM system. The broad participation from the...

Prolight Diagnostics
Press release7/3/2025, 6:00 AM

Emergers: Equity Research | PROLIGHT: Fully subscribed rights issue strengthens Psyros case ahead of commercial partnerships

Prolight Diagnostics
Regulatory press release7/2/2025, 6:05 AM

Prolight’s rights issue fully subscribed

Prolight Diagnostics
Regulatory press release6/30/2025, 3:50 PM

Prolight announces preliminary outcome of the rights issue

Prolight Diagnostics
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.